Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ViiV Poised To Take HIV PrEP Injectable In Late-Stage Trials

Executive Summary

ViiV Healthcare is set to start Phase III studies of its next-generation integrase inhibitor cabotegravir as a long-acting injectable for the prevention of HIV. The head-to-head study will compare it with Gilead’s market leading oral PrEP therapy Truvada in pre-exposure prohylaxis in both men and women.


Related Content

Truvada Sales To Rise On EU Okay In HIV Prevention; UK Use Uncertain
ViiV Starts Phase III With Two-Drug HIV Regimen In Naïve Patients
ViiV’s Visibility Grows And Pressure Mounts For What Comes Next


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts